SCHEMBL1017463

SCHEMBL1017463

O=C(CN1CCc2cc(-c3ccncc3)ccc2C1)N1CCN(C2CCC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.46
KDM4E B2RXH2 3/20 0.42
NAMPT P43490 2/20 0.41
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HRH3 Q9Y5N1 4/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KDM2B Q8NHM5 1/20 0.40
KCNH2 Q12809 1/20 0.39
PARP1 P09874 1/20 0.39
GPR142 Q7Z601 2/20 0.39
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CREBBP Q92793 1/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1016153 0.90 ALDH1A1 (0.48) MCHR1KDM4EALDH1A1MEN1KMT2A
SCHEMBL1018075 0.89 HRH3 (0.49) MCHR1KDM4EALDH1A1MEN1KMT2A
SCHEMBL1017130 0.89 HRH3 (0.43) MCHR1KDM4ENAMPTALDH1A1KMT2A
SCHEMBL1015085 0.89 ALDH1A1 (0.47) KDM4EALDH1A1MEN1KMT2AHRH3
SCHEMBL1019922 0.89 HRH3 (0.49) MCHR1ALDH1A1HRH3GAAPKM
SCHEMBL1014859 0.88 KDM4E (0.50) MCHR1KDM4EALDH1A1MEN1KMT2A
SCHEMBL1017560 0.87 MAPK1 (0.42) KDM4EALDH1A1HRH3GAAPKM
SCHEMBL1019051 0.87 HRH3 (0.47) MCHR1KDM4ENAMPTALDH1A1HRH3
SCHEMBL1017111 0.87 MAPT (0.42) KDM4EALDH1A1MEN1KMT2AHRH3
SCHEMBL1016580 0.87 HTT (0.43) ALDH1A1HRH3GAAPKMHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US claimed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
WO-2007106349-A2 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 MCHR1 287/4885KDM4E 2634/4885NAMPT 3087/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 MCHR1 287/4885KDM4E 2634/4885NAMPT 3087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.